Clearmind Medicine Announces Additional Positive Pre-Clinical Results for its Cocaine Addiction Treatment
Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF) announced promising pre-clinical results for its novel psychedelic compound MEAI as a treatment for cocaine addiction. The study, led by Professor Gal Yadid, showed that 60% of the animals in the trial exhibited a significant decrease in cocaine cravings after receiving MEAI. This finding aligns with previous research, underscoring MEAI's potential as a dedicated treatment for cocaine addiction. The company aims to address the pressing need for effective addiction therapies, highlighting MEAI's commercial potential.
- 60% of trial subjects showed significant decrease in cocaine cravings.
- Aligns with previous studies reinforcing MEAI's effectiveness.
- Potential to be the first dedicated cocaine addiction treatment.
- None.
The dedicated treatment indicated a significant decrease in cocaine craving in a sub- group that received Clearmind's MEAI
VANCOUVER, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced additional positive pre-clinical results for treatment for cocaine addiction using MEAI, its novel psychedelic molecule.
"We are very excited by these new results which further strengthen our previous results indicating the potential of our proprietary MEAI to treat cocaine addiction,” said Dr. Adi Zuloff-Shani, Clearmind's Chief Executive Officer. “As cocaine is extremely addictive and there is currently no dedicated treatment, I believe Clearmind is leading the way in this field. The results, even in this preliminary stage, also show the business impact as we need new and effective therapeutics, and these hold high commercial potential.”
The pre-clinical trial, led by Professor Gal Yadid and his team, from the Gonda Multidisciplinary Brain Research Center located at Bar Ilan University (Ramat Gan, Israel), was designed according to the self-administration paradigm, which is the gold-standard model for examining drug addiction and is based on operant conditioning.
In the present trial, animals were catheterized and trained to self-administer cocaine. After the establishment of the addiction model, rats underwent an extinction phase where no cocaine was administered and MEAI was given to the test group. Finally, a relapse phase was carried out where the addicted rats were reminded of the drug with a single administration and then the animals were returned to the self-administration habitat, without receiving the drug. The assumption is that the more an animal yearns to receive the drug, the more it will press on the active pedal.
The results identified a sub-group within the study, in a non-biased manner and with high integrity, which dramatically responded to the treatment, significantly decreasing the craving for cocaine, as compared to non-treated control group.
This sub-group, representing
About Clearmind Medicine Inc.
Clearmind is a new biotech company focused on the discovery and development of safe and novel psychedelic-derived therapeutics to treat alcohol use disorder and other pressing health challenges.
The Israeli- Canadian company holds several patents for the non-hallucinogenic compound MEAI (5-methoxy-2-aminoindane, a novel psychoactive substance). The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Clearmind has established a research collaboration with the Hebrew University of Jerusalem and Bar Ilan University. The partnerships aim to expand its R&D capabilities and discover new candidate treatments for other mental health issues.
Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol "CMND", the Frankfurt Stock Exchange under the symbol “CWY0” and on the OTC pink under the symbol "CMNDF".
For further information, please contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
FORWARD-LOOKING STATEMENTS:
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company's business strategy. There is no certainty that any of these events will occur. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. None of the Company’s product have received FDA approval and are not commercially available.
Investing into early-stage companies inherently carries a high degree of risk, and investment into securities of the Company shall be considered highly speculative.
Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
FAQ
What were the results of Clearmind's MEAI trial for cocaine addiction?
What is the significance of the trial results for Clearmind (CMNDF)?
Who conducted the pre-clinical trial for MEAI?
What does a decrease in cocaine craving imply for Clearmind's future?
